文献速递骨软组织肉瘤与黑色素瘤

纳帕芬尼联合曲美替尼治疗NRAS突变黑色素瘤的初步疗效证据:Ib期开放标签研究扩展臂结果

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
PubMed 文献 · J Clin Oncol · 2023-03-22

这项Ib期开放标签研究在NRAS突变黑色素瘤患者中评估纳帕芬尼联合曲美替尼的安全性和初步抗肿瘤活性。扩展期推荐剂量为纳帕芬尼200mg每日两次联合曲美替尼1mg每日一次或纳帕芬尼400mg每日两次联合曲美替尼0.5mg每日一次。联合方案显示出初步抗肿瘤活性。

要点

  • 扩展期30例患者均发生治疗相关不良事件,最常见为皮疹(80%,n=24)。
  • 纳帕芬尼200mg每日两次联合曲美替尼1mg每日一次组客观缓解率为46.7%。
  • 纳帕芬尼400mg每日两次联合曲美替尼0.5mg每日一次组客观缓解率为13.3%。

核心结论

  • 纳帕芬尼联合曲美替尼在NRAS突变黑色素瘤患者中显示出有前景的初步抗肿瘤活性。
  • 旨在降低皮肤相关事件发生率的预防策略正在研究中。

研究设计与样本

  • Ib期剂量递增/扩展研究(ClinicalTrials.gov标识符:NCT02974725)。
  • 递增期和扩展期分别入组36例和30例患者。
  • 递增期入组晚期/转移性KRAS或BRAF突变非小细胞肺癌及NRAS突变黑色素瘤患者,扩展期入组NRAS突变黑色素瘤患者。

主要发现

  • 递增期6例患者报告≥3级剂量限制性毒性,包括痤疮样皮炎(n=2)、斑丘疹(n=2)、脂肪酶升高(n=1)和Stevens-Johnson综合征(n=1)。
  • 扩展期所有30例患者均发生治疗相关不良事件,最常见为皮疹(80%,n=24),血肌酸磷酸激酶升高、腹泻和恶心各占30%(n=9)。
  • 纳帕芬尼200mg每日两次联合曲美替尼1mg每日一次组客观缓解率为46.7%(95%CI,21.3至73.4;15例中7例),中位缓解持续时间为3.75(95%CI,1.97至不可估计[NE])个月,中位无进展生存期为5.52个月。
  • 纳帕芬尼400mg每日两次联合曲美替尼0.5mg每日一次组客观缓解率为13.3%(95%CI,1.7至40.5;15例中2例),中位缓解持续时间为3.75(95%CI,2.04至NE)个月,中位无进展生存期为4.21个月。

关键数值与推荐

  • 扩展期推荐剂量为纳帕芬尼200mg每日两次联合曲美替尼1mg每日一次,以及纳帕芬尼400mg每日两次联合曲美替尼0.5mg每日一次。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available. PATIENTS AND METHODS: In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced/metastatic KRAS- or BRAF-mutant non-small-cell lung cancer (escalation arm) or NRAS-mutant melanoma (escalation and expansion arms). RESULTS: Thirty-six and 30 patients were enrolled in escalation and expansion, respectively. During escalation, six patients reported grade ≥3 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1). The recommended doses for expansion were naporafenib 200 mg twice a day plus trametinib 1 mg once daily and naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily. During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (30%, n = 9 each). In expansion, the objective response rate, median duration of response, and median progression-free survival were 46.7% (95% CI, 21.3 to 73.4; 7 of 15 patients), 3.75 (95% CI, 1.97 to not estimable [NE]) months, and 5.52 months, respectively, in patients treated with naporafenib 200 mg twice a day plus trametinib 1 mg once daily, and 13.3% (95% CI, 1.7 to 40.5; 2 of 15 patients), 3.75 (95% CI, 2.04 to NE) months, and 4.21 months, respectively, in patients treated with naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily. CONCLUSION: Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma. Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. de Braud F, Dooms C, Heist RS, et al. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. J Clin Oncol. 2023. PMID: 36947734. doi:10.1200/JCO.22.02018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。